Daily Sepsis Research Analysis
Analyzed 33 papers and selected 3 impactful papers.
Summary
Across today’s sepsis literature: a large network meta-analysis of 105 RCTs found no overall infection signal for GLP-1 receptor agonists or SGLT2 inhibitors, with high-dose canagliflozin uniquely linked to reduced sepsis risk. Mechanistic work identifies immune-activated oligodendrocyte precursor cells as drivers of cognitive dysfunction in sepsis-associated encephalopathy. A TLR4-inhibiting peptide (OH-CATH30) alleviates cachexia across sepsis, cancer, and chemotherapy models, suggesting a shared anti-inflammatory therapeutic pathway.
Research Themes
- Drug safety and infection risk with GLP-1 RAs and SGLT2 inhibitors
- Neuroinflammatory mechanisms in sepsis-associated encephalopathy
- Anti-inflammatory strategies for sepsis-related cachexia via TLR4
Selected Articles
1. The Effect of GLP-1 Receptor Agonist and SGLT2 Inhibitor on Infection Risk: Network Meta-Analysis.
Across 105 RCTs (n=219,283), GLP-1 receptor agonists and SGLT2 inhibitors did not increase overall infection risk compared with controls. Notably, high-dose canagliflozin (300 mg/day) was uniquely associated with reduced sepsis risk; findings were robust across subgroups and Bayesian analyses.
Impact: Provides high-level evidence on infection safety of widely used cardiometabolic agents and identifies a potential sepsis risk–reducing signal for canagliflozin.
Clinical Implications: Supports infection-safety reassurance for GLP-1 RAs/SGLT2i and suggests hypothesis-generating consideration of canagliflozin’s potential sepsis risk reduction in high-risk patients, pending confirmatory trials.
Key Findings
- Across 105 RCTs (219,283 participants), no overall increase in infections (including sepsis) with GLP-1 RAs or SGLT2 inhibitors versus control.
- High-dose canagliflozin 300 mg/day was the only agent associated with a reduced sepsis risk versus control, persisting in diabetic subgroups.
- Findings were robust in sensitivity, subgroup, meta-regression, and Bayesian analyses; treatment duration minimally affected outcomes.
Methodological Strengths
- Network meta-analysis of 105 RCTs with prespecified outcomes and PROSPERO registration
- Comprehensive sensitivity analyses including Bayesian modeling and subgroup/meta-regression
Limitations
- Event rates for severe infections like sepsis may be low in RCTs, limiting precision
- Heterogeneity in trial designs and adverse event reporting across studies
Future Directions: Prospective head-to-head trials or pragmatic studies should test the sepsis risk–reducing signal of canagliflozin and explore mechanistic bases for differential effects across agents.
BACKGROUND: Patients treated with GLP-1 receptor agonists and SGLT2 inhibitors often have underlying conditions that predispose them to infection. While these agents offer cardiometabolic benefits, concerns persist regarding their impact on infectious risk. Existing literature has not comprehensively assessed their dose-dependent influence on severe infections such as sepsis. OBJECTIVES: To investigate the effect of GLP-1 receptor agonists and SGLT2 inhibitors on infection risk. DATA SOURCES: PubMed, Embase, ClinicalKey, Cochrane CENTRAL, ProQuest, ScienceDirect, Web of Science, and ClinicalTrials.gov up to December 18, 2024. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials (RCTs) reporting target infection outcomes related to GLP-1 receptor agonists or SGLT2 inhibitors prescription. PARTICIPANTS: Individuals without evidence of ongoing infection at study initiation. INTERVENTIONS: GLP-1 receptor agonists or SGLT2 inhibitors ASSESSMENT OF RISK OF BIAS: Cochrane Risk of Bias Tool version 2.0 METHODS OF DATA SYNTHESIS: A frequentist random-effects model was used to assess the comparative incidence of infectious complications-classified as sepsis, abscess/gangrene, or other infections (e.g., pneumonia, UTI). Drop-out rates served to reflect acceptability. Sensitivity analyses included Bayesian modeling and subgroup analyses of diabetic status and treatment duration. RESULTS: Based on 105 RCTs with 219,283 participants, no significant association was found between GLP-1 receptor agonists or SGLT2 inhibitors and controls, except for high-dose canagliflozin (300 mg/day), which was the only intervention significantly associated with reduced sepsis risk versus control. This effect persisted in participants with diabetes. No significant associations were found between any other GLP-1 receptor agonist or SGLT2 inhibitor and risk of sepsis, abscess, gangrene, or other infections. Subgroup and meta-regression analyses confirmed robustness. Bayesian modeling yielded comparable results. Treatment duration had minimal influence on primary outcomes. CONCLUSIONS: This analysis identifies no significant evidence of infection-related adverse events related to GLP-1 receptor agonist or SGLT2 inhibitors prescription. TRIAL REGISTRATION: PROSPERO CRD42024628901.
2. Activation of oligodendrocyte precursor cells triggers cognitive dysfunction and synaptic defects in SAE.
In a mouse model of sepsis-associated encephalopathy, hippocampal OPCs exhibited immune activation with heightened inflammatory transcription and phagocytic capacity, contributing to synaptic pruning. Genetic ablation of OPCs in CA1 improved cognitive performance and alleviated synaptic structural and functional deficits.
Impact: Identifies OPCs as active contributors to SAE pathogenesis, shifting attention beyond neurons/microglia and nominating OPCs as a novel therapeutic target.
Clinical Implications: Suggests that modulating OPC activation or phagocytic signaling could be a strategy to prevent or treat cognitive impairment in sepsis-associated encephalopathy.
Key Findings
- OPCs in hippocampal CA1 showed immune activation in SAE, with increased inflammatory transcription and phagocytic capacity.
- Activated OPCs contributed to neuronal synaptic pruning in SAE mice.
- Selective ablation of OPCs (PDGFRa-Cre/ERT, AAV-flex-DTA) improved cognition and ameliorated synaptic structural and functional deficits.
Methodological Strengths
- Use of transgenic mice enabling cell-type specific OPC ablation
- Convergent phenotyping linking molecular activation, synaptic pathology, and behavior
Limitations
- Preclinical mouse model; translational relevance to human SAE requires validation
- Mechanistic pathways upstream and downstream of OPC activation were not fully dissected
Future Directions: Dissect signaling pathways governing OPC activation and phagocytosis in SAE and evaluate pharmacologic modulators to recapitulate the benefits of OPC ablation.
Sepsis-associated encephalopathy (SAE) is defined as a diffuse neurological dysfunction that occurs secondary to sepsis, in the absence of direct central nervous system infection, and is associated with high rates of incidence, mortality, and disability. Despite its clinical significance, the neuropathological mechanisms underlying SAE are not yet fully understood, making its pathogenesis a focal point of ongoing research. Oligodendrocyte precursor cells (OPCs), which are the most proliferative cell type within the central nervous system, primarily contribute to the generation of mature oligodendrocytes and are integral to myelination and the maintenance of myelin. Nevertheless, the role and pathological changes of OPCs during the acute phase of SAE remain inadequately characterized. This study illustrates that OPCs in the hippocampal CA1 region may undergo immune activation under SAE conditions, characterized by significantly elevated inflammatory transcription and phagocytic capacity. Additionally, activated OPCs in SAE mice may contribute to the synaptic pruning of neurons. By generating PDGFRa-Cre/ERT transgenic mice and conducting stereotactic injections of pAAV-EGFP-flex-DTA virus into the hippocampal CA1 region to selectively ablate OPCs, we observed a significant enhancement in cognitive function in SAE mice. This improvement is likely due to the alleviation of synaptic structural and functional impairments in neurons. Our findings indicate that OPCs play a critical role in the pathogenesis of SAE, highlighting their potential as a novel therapeutic target for this condition.
3. Peptide OH-CATH30 Mitigates Cachexia-Induced Muscle Atrophy via Modulation of TLR4-Associated Inflammation.
Across LPS-sepsis, cancer (4T1), and cisplatin cachexia models, TLR4 signaling was commonly upregulated. The TLR4-inhibiting peptide OH-CATH30 improved body/muscle weight, fiber CSA, and grip strength, while downregulating inflammatory and proteolytic pathways; pharmacologic TLR4 inhibition recapitulated these effects.
Impact: Demonstrates a shared TLR4-driven inflammatory axis in cachexia including sepsis and validates a peptide inhibitor that reverses muscle wasting across models.
Clinical Implications: Supports TLR4 as a therapeutic target for sepsis-related cachexia and prioritizes OH-CATH30-like strategies for future translational studies.
Key Findings
- Inflammation and protein degradation pathways were enriched across LPS-sepsis, 4T1 cancer, and cisplatin-induced cachexia, with upregulation of TLR4 pathway genes (Cd14, Tlr4, Irak4).
- OH-CATH30 increased MyHC, myotube diameter, body and muscle weight, CSA, and grip strength; it reduced Il6, Mstn, Trim63, Fbxo32, Bnip3, Gabarapl1, Ulk1, serum IL-6, atrogin1, and LC3II.
- TLR4 inhibitor TAK-242 recapitulated OH-CATH30’s protective effects, with no additive benefit when combined.
Methodological Strengths
- Multiple in vivo cachexia models (sepsis, cancer, chemotherapy) with convergent transcriptomic and functional readouts
- Mechanism supported by pharmacologic validation using a TLR4 inhibitor (TAK-242)
Limitations
- Preclinical study without human subjects; dosing, safety, and PK/PD of OH-CATH30 in humans are unknown
- Durability of effects and potential off-target immune modulation were not fully assessed
Future Directions: Advance to GLP/toxicology and dose-finding studies, and test TLR4-targeted anti-cachexia strategies in early-phase clinical trials in septic and oncologic populations.
BACKGROUND: Cachexia, characterized by severe weight loss and muscle atrophy, frequently occurs in chronic conditions such as sepsis, cancer and chemotherapy, with limited effective treatments. Despite similar clinical manifestations, the underlying mechanisms across different disease contexts remain unclear. Identifying common pathways could lead to novel therapies. This study examines the role of Toll-like receptor 4 (TLR4), which is upregulated in various cachexia models, and assesses the therapeutic potential of the TLR4-inhibiting peptide OH-CATH30 in mitigating muscle atrophy. METHODS: In vivo models using 8-week-old mice treated with lipopolysaccharide (LPS), 4T1 tumour cells and cisplatin were used to investigate common pathways in cachexia. In vitro models were established by treating C2C12 myotubes with TNF-α, 4T1 culture supernatants and cisplatin. OH-CATH30's effects on muscle atrophy were assessed by measuring myotube diameter, grip strength, muscle weight and muscle fibre cross-sectional area (CSA) via H&E staining. RNA-seq, qPCR, ELISA and Western blotting were performed to explore pathways in cachexia-induced muscle atrophy and OH-CATH30's action mechanism. RESULTS: Transcriptomic analysis showed significant enrichment of inflammation and protein degradation pathways in skeletal muscle in LPS-induced sepsis, 4T1 tumour-induced cancer cachexia and cisplatin-induced cachexia models, with upregulated expression of TLR4 pathway genes such as Cd14, Tlr4 and Irak4 (p < 0.05). In myotube atrophy models induced by TNF-α, 4T1 and cisplatin, OH-CATH30 significantly increased MyHC protein levels (p < 0.05) and myotube diameter (p < 0.05). In mouse cachexia models induced by LPS, 4T1 and cisplatin, OH-CATH30 treatment significantly increased body weight (p < 0.05), muscle weight (p < 0.001), CSA (p < 0.05) and improved grip strength (p < 0.05). Transcriptomic analysis further revealed that OH-CATH30 treatment downregulated expression of inflammation and protein degradation-related genes across all cachexia models. In 4T1-treated mice, qPCR confirmed OH-CATH30 reduced mRNA levels of Il6 (p = 0.05), Mstn (p < 0.0001) and protein degradation genes such as Trim63, Fbxo32, Bnip3, Gabarapl1 and Ulk1 (p < 0.05). ELISA showed reduced serum IL-6 levels, and Western blot confirmed downregulation of atrogin1 (p < 0.05) and autophagy marker LC3II (p < 0.05) with OH-CATH30 treatment. Pharmacological inhibition of TLR4 using TAK-242 recapitulated the protective effects of OH-CATH30, with no additive benefit observed (p > 0.05). CONCLUSIONS: Our findings underscore the critical role of TLR4 signalling in cachexia-associated muscle wasting across different disease contexts and demonstrate the efficacy of OH-CATH30, a TLR4 inhibitor, in alleviating muscle atrophy in various cachexia models.